Comparison of the lymphoid toxicities of mitobronitol and busulphan in mice

Reduced B cell toxicity and improved thymic recovery as possible contributors to the reduced risk for complications following BMT with mitobronitol preconditioning

J. Szebeni, K. Barna, F. Uher, J. Milosevits, K. Pálóczi, D. Gaál, G. G. Petrányi, E. Kelemen

Research output: Article

8 Citations (Scopus)

Abstract

It has previously been reported that the use of mitobronitol (dibromomannitol, DBM) instead of busulphan (BU) for myelosuppression is associated with significantly decreased risk for several complications of allogeneic bone marrow transplantation in accelerated chronic granulocytic leukemia. In exploring the pharmacologic basis for this observation, we have compared the acute and subacute cytotoxicities of DBM and BU on the spleen and thymus of mice. While there was comparable early (day 3) weight loss in both organs following these treatments, splenic B cells exhibited significantly less damage, and thymic regeneration (over weeks) was significantly faster following DBM treatment than with BU. These observations raise the possibility that improved post-BMT immune recovery could contribute to the clinical benefits observed with DBM-preconditioning.

Original languageEnglish
Pages (from-to)1769-1774
Number of pages6
JournalLeukemia
Volume11
Issue number10
Publication statusPublished - 1997

Fingerprint

Mitobronitol
Busulfan
B-Lymphocytes
Homologous Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone Marrow Transplantation
Thymus Gland
Weight Loss
Regeneration
Spleen
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

@article{84761593c9ce4f90a176b0cb91cd8dd0,
title = "Comparison of the lymphoid toxicities of mitobronitol and busulphan in mice: Reduced B cell toxicity and improved thymic recovery as possible contributors to the reduced risk for complications following BMT with mitobronitol preconditioning",
abstract = "It has previously been reported that the use of mitobronitol (dibromomannitol, DBM) instead of busulphan (BU) for myelosuppression is associated with significantly decreased risk for several complications of allogeneic bone marrow transplantation in accelerated chronic granulocytic leukemia. In exploring the pharmacologic basis for this observation, we have compared the acute and subacute cytotoxicities of DBM and BU on the spleen and thymus of mice. While there was comparable early (day 3) weight loss in both organs following these treatments, splenic B cells exhibited significantly less damage, and thymic regeneration (over weeks) was significantly faster following DBM treatment than with BU. These observations raise the possibility that improved post-BMT immune recovery could contribute to the clinical benefits observed with DBM-preconditioning.",
keywords = "Bone marrow transplantation, Busulphan, Chronic granulocytic leukemia, Dibromomannitol, Myelosuppression",
author = "J. Szebeni and K. Barna and F. Uher and J. Milosevits and K. P{\'a}l{\'o}czi and D. Ga{\'a}l and Petr{\'a}nyi, {G. G.} and E. Kelemen",
year = "1997",
language = "English",
volume = "11",
pages = "1769--1774",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Comparison of the lymphoid toxicities of mitobronitol and busulphan in mice

T2 - Reduced B cell toxicity and improved thymic recovery as possible contributors to the reduced risk for complications following BMT with mitobronitol preconditioning

AU - Szebeni, J.

AU - Barna, K.

AU - Uher, F.

AU - Milosevits, J.

AU - Pálóczi, K.

AU - Gaál, D.

AU - Petrányi, G. G.

AU - Kelemen, E.

PY - 1997

Y1 - 1997

N2 - It has previously been reported that the use of mitobronitol (dibromomannitol, DBM) instead of busulphan (BU) for myelosuppression is associated with significantly decreased risk for several complications of allogeneic bone marrow transplantation in accelerated chronic granulocytic leukemia. In exploring the pharmacologic basis for this observation, we have compared the acute and subacute cytotoxicities of DBM and BU on the spleen and thymus of mice. While there was comparable early (day 3) weight loss in both organs following these treatments, splenic B cells exhibited significantly less damage, and thymic regeneration (over weeks) was significantly faster following DBM treatment than with BU. These observations raise the possibility that improved post-BMT immune recovery could contribute to the clinical benefits observed with DBM-preconditioning.

AB - It has previously been reported that the use of mitobronitol (dibromomannitol, DBM) instead of busulphan (BU) for myelosuppression is associated with significantly decreased risk for several complications of allogeneic bone marrow transplantation in accelerated chronic granulocytic leukemia. In exploring the pharmacologic basis for this observation, we have compared the acute and subacute cytotoxicities of DBM and BU on the spleen and thymus of mice. While there was comparable early (day 3) weight loss in both organs following these treatments, splenic B cells exhibited significantly less damage, and thymic regeneration (over weeks) was significantly faster following DBM treatment than with BU. These observations raise the possibility that improved post-BMT immune recovery could contribute to the clinical benefits observed with DBM-preconditioning.

KW - Bone marrow transplantation

KW - Busulphan

KW - Chronic granulocytic leukemia

KW - Dibromomannitol

KW - Myelosuppression

UR - http://www.scopus.com/inward/record.url?scp=0030665240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030665240&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 1769

EP - 1774

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 10

ER -